With regard to the Patented Medicines Prices Review Board (PMPRB) and the proposed amendments to the “Patented Medicines Regulations”, also referred to as the PMPRB Guidelines, since January 1, 2017: (a) how many organizations, advocacy groups, and members of industry or stakeholders have been consulted, both sum total and broken down in an itemized list by (i) name, (ii) summary of their feedback, (iii) date; (b) how many stakeholders expressed positive feedback about the proposed guidelines; (c) how many stakeholders expressed negative feedback about the proposed guidelines; (d) what is the threshold of negative feedback needed to delay implementation of the proposed guidelines as has been done previously in mid 2020, and start of 2021; (e) have there been any requests made by PMPRB executives to Health Canada officials to delay the implementation of the proposed regulations; and (f) how many times were these requests rejected by Health Canada officials?
In the House of Commons on June 16th, 2021. See this statement in context.